Living Medical Textbook - Hematology - Projects In Knowledge - Insights into Managing Leukemia Table of Contents

Very Often

Not Very Often

Use a tyrosine kinase inhibitor in the initial treatment of chronic phase CML

Test for the presence of the BCR/ABL oncogene in CML patients

Treat AML with stem cell transplantation

Treat AML with high-dose cytarabine regimens

Living Medical
Textbook
From Projects In Knowledge

Hematology

Insights into Managing Leukemia

Table of Contents | CME Information | Technical Requirements | Login

/1921/images/PIKEduInit.gif [YES]/1921/iPhoneAd/1921iPhoneAd.gif [NO]

Chapter 1
Release date: May 14, 2010

Chapter 2
Release date: May 14, 2010

Chapter 3
Myeloid Leukemia
Last Reviewed: May 14, 2010

–	Introduction
–	Treatment of Chronic Myelogenous Leukemia
–	Acute Myeloid Leukemia
–	Treatment of AML
–	References

This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation.

Hematology News powered by

This CME program will include a brief pretest. Please start now by answering these 4 questions:

Which of the following statements about chronic myeloid leukemia (CML) is false? *

	Decreased apoptosis contributes to increased myeloid mass
	A tyrosine kinase is produced constitutively, leading to proliferation
	Metaphase leukemic cells uniformly exhibit a normal karyotype, with the exception of the translocation known as the Philadelphia chromosome
	Immature blast cells are released prematurely into the circulation

For untreated CML, the disease: *

	May take a variable course, with some patients attaining a normal lifespan
	Inevitably progresses to an aggressive blast phase in an average of about 4 years
	Leads to myelodysplastic syndromes within 1 to 2 years
	Always responds favorably to tyrosine kinase inhibitors if cells are proliferating rapidly

A 50-year-old woman with acute myeloid leukemia (AML) relapses 2 years after complete response to induction therapy with cytarabine plus daunorubicin. Her AML is positive for core-binding factor (CBF). What would be a reasonable next step? *

	Allogeneic stem cell transplantation
	Therapy with high-dose (3 g/m²) cytarabine plus mitoxantrone
	Imatinib 800 mg/day
	Dasatinib 600 mg BID

How often do you currently use each of the following clinical practice strategies? *